Search results for "DOSAGE FORMS"

showing 10 items of 39 documents

New methods of delivery of amphotericin B.

1993

Fungal infections continue to be a major problem in the management of immunocompromised patients. Despite its formidable toxicity and treatment failures, amphotericin B is still the drug of choice for most of these infections. One strategy for reducing the toxicity of amphotericin B and thus permitting administration of higher doses is that of using less toxic formulations. Entrapping amphotericin B into liposomes or binding it to other substances reduces its toxicity to host cells, whereas the selective binding of amphotericin B to ergosterol preserves its toxicity to fungal cells. Adding fungus-specific antibodies to such liposomes may further increase the efficiency of drug targeting. Th…

Microbiology (medical)DrugTime Factorsmedia_common.quotation_subjectPharmacologyAspergillosisRoute of administrationImmunocompromised HostAmphotericin BAmphotericin BMedicineAnimalsAspergillosisHumansAdministration Intranasalmedia_commonAerosolsDosage Formsbusiness.industrymedicine.diseaseClinical trialInfectious DiseasesTargeted drug deliveryMycosesToxicityNasal administrationbusinessmedicine.drugClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Simultaneous dissolution profiles of two drugs, sulfadiazine-trimethoprim and amitriptyline-perphenazine, in solid oral dosage forms by a FIA manifol…

2002

The simultaneous determination of two dissolution profiles with the aid of a Flow Injection Analysis assembly has been applied to: (a) sulfadiazine-trimethoprim in tablets and (b) amitriptyline-perphenazine in sugar coated pills. The selected combinations are drugs which have overlapping UV-vis spectra. The officially proposed procedure from the pharmacopoeias has been adapted for the FIA methodology and derivative spectrophotometry and zero crossing. Preliminary experiments on the suitability of the simultaneous determination of both drugs were performed. The empirical profiles were adjusted by regression analysis using different approaches. The 3-parameter plot method was finally selected…

PerphenazineAmitriptylineClinical BiochemistryAnalytical chemistryAdministration OralSulfadiazinePharmaceutical ScienceDerivativeTrimethoprimDosage formAnalytical ChemistrySpectrophotometryDrug DiscoverymedicineDissolutionSpectroscopyDosage FormsFlow injection analysisAmitriptyline/perphenazineChromatographymedicine.diagnostic_testChemistryDetectorDrug CombinationsSolubilitySpectrophotometryFlow Injection AnalysisPerphenazinemedicine.drugJournal of Pharmaceutical and Biomedical Analysis
researchProduct

Oral Solid Dosage Form Disintegration Testing — The Forgotten Test

2014

Since its inception in the 1930s, disintegration testing has become an important quality control (QC) test in pharmaceutical industry, and disintegration test procedures for various dosage forms have been described by the different pharmacopoeias, with harmonization among them still not quite complete. However, because of the fact that complete disintegration does not necessarily imply complete dissolution, much more research has been focused on dissolution rather than on disintegration testing. Nevertheless, owing to its simplicity, disintegration testing seems to be an attractive replacement to dissolution testing as recognized by the International Conference on Harmonization guidelines, …

Dosage FormsSolubilityRisk analysis (engineering)Test proceduresChemistry PharmaceuticalPharmaceutical ScienceDissolution testingBusinessDosage formIntestinal absorptionBiopharmaceuticsTest (assessment)Journal of Pharmaceutical Sciences
researchProduct

Oral local drug delivery and new perspectives in oral drug formulation

2012

Modern pharmaceutical science has provided us with a wide range of substances to be administered with a wide large variety of dosage forms. Local drug delivery systems have been used for a long time; in particular, for the local therapy of diseases affecting the oral cavity. Although these diseases are often extremely responsive to local therapy, the mouth often presents various difficulties in the application of topical compounds (owing to saliva and the mouth's different functions), resulting in a short retention time of dosage forms with a consequent low therapeutic efficacy. To resolve these limitations, research today concentrates on the development of bioadhesive formulations. This re…

medicine.medical_specialtyChemistry PharmaceuticalBioadhesiveAdministration SublingualPharmaceutical Preparations DentalPharmacologyPermeabilityDosage formPathology and Forensic MedicineDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheAdhesivesAdministration MucosalHumansMedicineRadiology Nuclear Medicine and imagingDentistry (miscellaneous)Pharmaceutical sciencesOral mucosaIntensive care medicineDosage Formsbusiness.industryMouth MucosaAdministration BuccalBuccal administrationDrug delivery Buccal mucosa Buccal dosage formsmedicine.anatomical_structureSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverySurgeryOral SurgerybusinessRetention timeOral retinoid
researchProduct

In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration

2019

The availability of in vitro tools that are constructed on the basis of a detailed knowledge of key aspects of gastrointestinal (GI) physiology and their impact on formulation performance and subsequent drug release behaviour is fundamental to the success and efficiency of oral drug product development. Over the last six years, the development and optimization of improved, biorelevant in vitro tools has been a cornerstone of the IMI OrBiTo (Oral Biopharmaceutics Tools) project. By bringing together key industry and academic partners, and by linking tool development and optimization to human studies to understand behaviour at the formulation/GI tract interface, the collaboration has enabled …

Process managementUPPER GASTROINTESTINAL-TRACTAdministration OralPharmaceutical Science02 engineering and technologyWATER DIFFUSIVITYModels Biological030226 pharmacology & pharmacyDosage formBiopharmaceutics03 medical and health sciences0302 clinical medicineDISINTEGRATION TESTERHumansPharmacology & PharmacyWEAK BASESIntersectoral CollaborationBiologyTEST DEVICEDosage FormsALBENDAZOLE CONCENTRATIONSScience & TechnologyHuman studiesbusiness.industryBiopharmaceuticsFED STATE CONDITIONSGeneral Medicine021001 nanoscience & nanotechnologyRELEASE TABLETSGastrointestinal TractPharmaceutical PreparationsGastrointestinal AbsorptionGeneral partnershipSOLID DISPERSIONNew product developmentDrug releaseIntersectoral Collaboration0210 nano-technologybusinessLife Sciences & BiomedicineUPPER SMALL-INTESTINEOral retinoidForecastingBiotechnology
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Codeine Phosphate

2014

The present monograph reviews data relevant to applying the biowaiver procedure for the approval of immediate-release multisource solid dosage forms containing codeine phosphate. Both biopharmaceutical and clinical data of codeine were assessed. Solubility studies revealed that codeine meets the "highly soluble" criteria according to World Health Organization (WHO), the European Medicines Agency (EMA), and the United States Food and Drug Administration (US FDA). Codeine's fraction of dose absorbed in humans was reported to be high (>90%) based on cumulative urinary excretion of drug and drug-related material following oral administration. The permeability of codeine was also assessed to be …

Dosage FormsDrugCodeinebusiness.industrymedia_common.quotation_subjectCodeinePharmaceutical ScienceCodeine PhosphateBioequivalencePharmacologyDosage formBioavailabilityExcipientsBiopharmaceuticalSolubilityOral administrationmedicineHumansbusinessmedicine.drugmedia_commonJournal of Pharmaceutical Sciences
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Folic Acid.

2018

This work presents a review of literature and experimental data relevant to the possibility of waiving pharmacokinetic bioequivalence studies in human volunteers for approval of immediate-release solid oral pharmaceutical forms containing folic acid as the single active pharmaceutical ingredient. For dosage forms containing 5 mg folic acid, the highest dose strength on the World Health Organization Essential Medicines List, the dose/solubility ratio calculated from solubility studies was higher than 250 mL, corresponding to a classification as "not highly soluble." Small, physiological doses of folic acid (≤320 μg) seem to be absorbed completely via active transport, but permeability data f…

Pharmaceutical ScienceAdministration OralBiological AvailabilityBioequivalencePharmacology030226 pharmacology & pharmacyDosage formPermeabilityBiopharmaceuticsExcipients03 medical and health sciences0302 clinical medicineFolic AcidPharmacokineticsCell Line TumorHumansSolubilityActive ingredientDosage FormsChemistryBiopharmaceutics Classification SystemBioavailabilityFolic acidSolubilityTherapeutic Equivalency030220 oncology & carcinogenesisCaco-2 CellsJournal of pharmaceutical sciences
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.

2019

Literature data and results of experimental studies relevant to the decision to allow waiver of bioequivalence studies in humans for the approval of immediate release solid oral dosage forms containing cephalexin monohydrate are presented. Solubility studies were performed in accordance with the current biowaiver guidelines of the Food and Drug Administration, World Health Organization and European Medicines Agency, taking the degradation at some pH values into consideration. Together with solubility and permeability data for cephalexin monohydrate from the literature, it was demonstrated to be a Biopharmaceutics Classification System Class 1 drug. The pharmacokinetic behavior, results of b…

Drugmedia_common.quotation_subjectPharmaceutical ScienceExcipientAdministration OralBiological Availability02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyDosage formPermeabilityBiopharmaceutics03 medical and health sciences0302 clinical medicinemedicineBiopharmaceutics Classification System (BCS)HumansRegulatory scienceLADME characteristicsmedia_commonActive ingredientcephalexin monohydrateDosage FormsbioequivalenceCephalexinexcipientsbusiness.industryBiopharmaceutics021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemSolubilityTherapeutic Equivalencyregulatory science0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct

Computational Fluid Dynamics Simulation of Hydrodynamics and Stresses in the PhEur/USP Disintegration Tester Under Fed and Fasted Fluid Characteristi…

2015

ABSTRACT: Disintegration of oral solid dosage forms is a prerequisite for drug dissolution and absorption and is to a large extent dependent on the pressures and hydrodynamic conditions in the solution that the dosage form is exposed to. In this work, the hydrodynamics in the PhEur/USP disintegration tester were investigated using computational fluid dynamics (CFD). Particle image velocimetry was used to validate the CFD predictions. The CFD simulations were performed with different Newtonian and non-Newtonian fluids, representing fasted and fed states. The results indicate that the current design and operating conditions of the disintegration test device, given by the pharmacopoeias, are n…

Pharmaceutical ScienceComputational fluid dynamicsDosage formsymbols.namesakeNewtonian fluidShear stressPressureTechnology PharmaceuticalDissolution testingComputer SimulationDosage FormsChemistrybusiness.industryViscosityReynolds numberMechanicsFastingModels TheoreticalBody FluidsParticle image velocimetrySolubilitysymbolsHydrodynamicsCurrent (fluid)businessRheologyShear StrengthTabletsJournal of pharmaceutical sciences
researchProduct

Hydroxypropylmethylcellulose films for the ophthalmic delivery of diclofenac sodium

2012

Abstract Objectives The aim of this study was to prepare diclofenac/hydroxypropylmethylcellulose (HPMC) and diclofenac-loaded nanoparticles/HPMC films as potential systems for ocular delivery. Methods Two different concentration of the polymer were used: 1.5 and 2.0% w/v. Chitosan–hyaluronic acid nanoparticles were prepared by the ionotropic gelation technique. Nanoparticles were characterized by transmission electron microscopy, dynamic light scattering, drug encapsulation efficiency and rheological studies. In-vitro drug studies and corneal penetration release studies were carried out. Drug release mechanism was finally evaluated by fitting the Ritger and Peppas equation to data. In addit…

DiclofenacPolymersPharmaceutical ScienceNanoparticleAdministration OphthalmicMethylcellulosePharmacologyPermeabilityDosage formDrug Delivery SystemsHypromellose DerivativesDiclofenacDynamic light scatteringmedicineHyaluronic AcidDosage FormsPharmacologychemistry.chemical_classificationChitosanChemistryAnti-Inflammatory Agents Non-SteroidalDiclofenac SodiumPolymerPermeationHypromellose DerivativesNanoparticlesmedicine.drugNuclear chemistryJournal of Pharmacy and Pharmacology
researchProduct